Opus Genetics Inc 2026年季度报告

Form 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-34079 Opus Genetics, Inc. (Exact name of Registrant as specified in its charter) 11-3516358 (State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) 8 Davis Drive, Suite 220Durham, NC27713(Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (984) 884-6030 N/A(Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smallerreporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated filerNon-accelerated filerAccelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo The number of outstanding shares of the registrant’s common stock as of August3, 2026 was 83,195,823. PART 1 – FINANCIAL INFORMATION Item 1.Financial Statements3Condensed Consolidated Balance Sheets as ofJune 30, 2026(unaudited) and December 31, 20253Condensed Consolidated Statements of Comprehensive Loss for the three and six months endedJune 30,2026and 2025 (unaudited)4Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ (Deficit)Equity for the three and six months endedJune 30, 2026and 2025 (unaudited)5Condensed Consolidated Statements of Cash Flows for the six months endedJune 30, 2026 and 2025(unaudited)6Notes to Condensed Consolidated Financial Statements (unaudited)7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures About Market Risk48Item 4.Controls and Procedures48 Item 1.Legal Proceedings49Item 1A.Risk Factors49Item 2.Unregistered Sales of Equity Securities and Use of Proceeds49Item 3.Defaults Upon Senior Securities49Item 4.Mine Safety Disclosures49Item 5.Other Information49Item 6.Exhibits50 PART I – FINANCIAL INFORMATION Opus Genetics, Inc.Condensed Consolidated Balance Sheets(in thousands, except share amounts and par value) Opus Genetics, Inc.Condensed Consolidated Statements ofComprehensive Loss(in thousands, except share and per share amounts)(Unaudited) Opus Genetics, Inc.Condensed Consolidated Statements of Changes inConvertible Preferred Stock and Stockholders’ (Deficit) Equity(in thousands, except share amounts)(Unaudited) Opus Genetics, Inc.Condensed Consolidated Statements of Cash Flows(in thousands) 1.Company Description and Summary of Significant Accounting Policies Nature of Business and Basis of Presentation Opus Genetics, Inc. (the “Company” or “Opus”), a Delaware corporation formerly known as Ocuphire Pharma, Inc., is a clinical-stagebiopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinaldiseases (“IRDs”). The Company also has a small molecule therapy for other ophthalmic disorders. The Company’s headquarters islocated in Durham, North Carolina. The Company’s pipeline is centered on adeno‑associated virus (“AAV”) based gene therapy programs addressing genetically definedforms of IRD, including OPGx‑LCA5, which is currently being evaluated for the treatment of Leber congenital amaurosis caused bymutations in the LCA5 gene, and OPGx‑BEST1, which is currently being evaluated for retinal diseases associated with mutations inthe BEST1 gene. In addition, the Company is